{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T04:07:26Z","timestamp":1748837246135,"version":"3.37.3"},"reference-count":15,"publisher":"FapUNIFESP (SciELO)","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  BACKGROUND:  In Brazil, since 2015, the treatment of hepatitis C is provided by SUS (Public Health System) with direct-acting antiviral (DAA).  OBJECTIVE:  To describe the rate of non-adherence patients to hepatitis C treatment by DAA, investigating the epidemiological data in a large database from Curitiba, Brazil.  METHODS:  Retrospective study with patients treated between January 2015 and June 2019. Patients were considered adherent when received all medication doses during their treatment. The following data were evaluated: gender, age, type of treatment, period of treatment, presence of diabetes or HIV, previous therapy, originated from SUS or private medicine, fibrosis grade and HCV genotype.  RESULTS:  1248 patients (56.8% males) were studied and 102\/1248 (8.2%) were non-adherent to treatment. Age or gender not influenced significantly; 10.2% patients from SUS and 3.7% individuals from private medicine were non-adherent (P&lt;0.0001; OR=2.9; CI95%=1.6-9.1); 13.1% patients were co-infected with HIV and among them, 15.9% abandoned treatment. Individuals without co-infection presented 7.0% of non-adherence (P&lt;0.0001; OR=2.5; CI=1.5-4.1). All the other variables showed no differences in the adhesion rate.  CONCLUSION:  Our study showed that 8.2% of patients were non-adherent to HCV treatment, and that patients from the Public Health System and co-infected with HIV were significantly less adherent.<\/jats:p>","DOI":"10.1590\/s0004-2803.202100000-83","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:41:01Z","timestamp":1639140061000},"page":"456-460","source":"Crossref","is-referenced-by-count":1,"title":["NON-ADHERENCE TO HEPATITIS C TREATMENT: A BRAZILIAN REPORT"],"prefix":"10.1590","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-557X","authenticated-orcid":false,"given":"Claudia Alexandra Pontes","family":"IVANTES","sequence":"first","affiliation":[{"name":"Centro de Orienta\u00e7\u00e3o e Aconselhamento (COA),  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-1341","authenticated-orcid":false,"given":"Bernardo Carvalho da","family":"SILVA","sequence":"additional","affiliation":[{"name":"Universidade Positivo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4267-1331","authenticated-orcid":false,"given":"Gabriel Gon\u00e7alves","family":"ACOSTA","sequence":"additional","affiliation":[{"name":"Universidade Positivo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5900-9056","authenticated-orcid":false,"given":"Fabiane Beatriz Neves El","family":"TAWIL","sequence":"additional","affiliation":[{"name":"Centro de Orienta\u00e7\u00e3o e Aconselhamento (COA),  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1234-8093","authenticated-orcid":false,"given":"Renato","family":"NISIHARA","sequence":"additional","affiliation":[{"name":"Universidade Positivo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2021,10]]},"reference":[{"year":"2020","series-title":"Hepatitis C","key":"ref1"},{"year":"2020","series-title":"Boletim Epidemiol\u00f3gico de Hepatites Virais 2019","key":"ref2"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany MG","year":"2020","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bjid.2019.01.006","article-title":"How are HCV-infected patients being identified in Brazil: a multicenter study","volume":"23","author":"Portari-Filho LH","year":"2019","journal-title":"Braz J Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.aohep.2019.08.001","article-title":"Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil","volume":"18","author":"Lobato CMO","year":"2019","journal-title":"Ann Hepatol"},{"series-title":"Towards the elimination of hepatitis B and C by 2030. Draft WHO Global Hepatitis Strategy, 2016-2021","key":"ref6"},{"key":"ref7","first-page":"1170","article-title":"Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair: EASL Governing Board representative; Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/hep.29308","article-title":"High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center","volume":"66","author":"Falade-Nwulia O","year":"2017","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jceh.2018.07.004","article-title":"New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials","volume":"9","author":"Pecoraro V","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jceh.2018.01.001","article-title":"Hepatitis C Continuum of Care in a Treatment Center in Sub-Saharan Africa","volume":"8","author":"Luma HN","year":"2018","journal-title":"J Clin Exp Hepatol"},{"key":"ref11","first-page":"SP198","article-title":"Improving HCV cure rates in HIV-coinfected patients - a real-world perspective","volume":"22","author":"Lakshmi S","year":"2016","journal-title":"Am J Manag Care"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12429","article-title":"Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy","volume":"18","author":"Milazzo L","year":"2017","journal-title":"HIV Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1001\/archinte.160.14.2101","article-title":"Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence","volume":"160","author":"DiMatteo MR","year":"2000","journal-title":"Arch Intern Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study","volume":"67","author":"Rockstroh JK","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugpo.2017.05.025","article-title":"Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada","volume":"47","author":"Mason K","year":"2017","journal-title":"Int J Drug Policy"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v58n4\/1678-4219-ag-58-04-456.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:41:15Z","timestamp":1639140075000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032021000400456&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["S0004-28032021000400456"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.202100000-83","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"type":"electronic","value":"1678-4219"},{"type":"print","value":"0004-2803"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}